This global summary is divided into two sections. The first provides information on the reported incidence of vaccine preventable diseases on a regional basis, and the second part contains individual country profiles, indicators of the performance of immunization systems, and a time series of the reported incidence and immunization coverage for all countries
This report raises awareness of the global burden of mental and neurological disorders, and its cost in human, social and economic terms. It also aims to dismantle the barriers which prevent millions of sufferers of mental and neurological disorders from receiving the treatment they need and deserve. The report describes how mental health problems can be solved (eg. by drug therapy, psycho-social rehabilitation and psychotherapy, vocational rehabilitation, housing), and gives examples of the effectiveness of these treatments for a wide range of mental disorders
This toolkit adds to the knowledge base to support analysts and decision-makers in their work to mainstream HIV/AIDS as a major item on countries' development agenda, and mobilize the resources needed to expand promising interventions and approaches in the fight against the epidemic. The toolkit offers a unifying framework for analysing HIV/AIDS in the context of PRSPs, as well as examples of how the issue has been treated in the first generation of PRSPs, interim PRSPs and debt relief agreements. It gives country officials and their partners highly relevant information that they can use in developing inputs for similar documents in their own countries. [adapted from Foreword]
This annotated bibliography aims to inform people in the health sector, with no particular legal background, about the impact of globalization and trade agreements on access to drugs, and the growing importance of this issue. It directs the reader to key reports, books and articles from technical and scientific journals, both general references and specific country studies. Details of some useful web sites are also given.
These instructions describe in detail how to apply to procure lower priced anti-TB drugs through the WHO Green Light Committee. See also Guidelines for establishing DOTS-plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB)
This report assesses the place of health in global economic development. Health is understood to be a central goal and an important outcome of development. It is also important to invest in health to promote economic development and poverty reduction. The report suggests a new strategy for investing in health for economic development in the world's poorests countries, based upon a new global partnership of developed and developing countries. Two important initiatives are required: a significant scaling up of resources spent in the health sector by poor countries and donors, and tackling non-financial obstacles, which limit capacity in poor countries to deliver health services
In this new edition guidelines are given on developing a national drug policy - a crucial ingredient in every country's national health strategy and an invaluable framework to identify national goals and commitments. This expanded and extensively revised second edition discusses key policy components. These include the selection of essential drugs, affordability , finance and supply, regulation and quality assurance, rational use, research, human resources, monitoring and evaluation.
Each chapter presents useful advice and references to other sources of more detailed technical information. A valuable resource for health professionals, policy-makers and researchers, the publication takes readers through the process of planning, developing, implementing and monitoring a comprehensive policy framework based on a country's unique needs, priorities and resources
This strategy provides a framework of interventions to stimulate the prevention of infection, to slow the emergence of resistance and to reduce the spread of resistant microorganisms, in order to reduce the impact of resistance on health and health care costs, while improving access to existing agents and encouraging the development of new agents